Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

General Information

Viralytics Limited
VLA
http://www.viralytics.com
Biotechnology
81
184

Current Price Data+

Current Price Open High Low Last Close Volume Price Movement
$0.44 $0.44 $0.45 $0.44 $0.43 356253 $0.01 ( 2.33% )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Current Broker Consensus Recommendation

Buy
23/04/2015
1

Company Overview

Business Description
Viralytics Ltd (VLA) is an Australian biotechnology company focusing on developing oncolytic virotherapy for the treatment of a range of cancers. VLA’s principal asset is the intellectual property relating to CAVATAK, an Oncolytic Virus Technology, and is in current product development and pipeline. VLA holds granted patents in all major markets including the USA and Europe.
Strategy Analysis
--

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016 F 0.0 -5.4 0.0% 0.0 0.0 0.0% 0.0%
2015 F 0.0 -5.3 0.0% 0.0 0.0 0.0% 0.0%
2014 A -5.5 -4.6 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Bionomics (BNO) $167M 0.0000 0.0000 0.0000 51.9481 0.0000 4.0568 0.00% 0.00% 0.00%
CSL (CSL) $43,999M 0.0899 0.3345 0.0817 32.8421 24.6098 22.7509 1.28% 1.69% 1.93%
Mesoblast (MSB) $1,199M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Sirtex Medical (SRX) $1,308M 0.2906 0.6085 0.2535 56.0048 34.8186 27.7771 0.61% 0.81% 1.22%
Viralytics (VLA) $79M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 2.80 10.00
Market 0.92 14.80 1.04 1.09
Sector 0.83 16.80 2.79 1.35

Directors

Name Position Start Date
Dr Malcolm McColl Chief Executive Officer, Managing Director 08/09/2014
Mr Paul Hopper Non-Executive Chairman 04/09/2008
Mr Peter R Turvey Non-Executive Director 08/09/2014
Dr Leonard Post Non-Executive Director 21/11/2011

Management

Name Position
Robert Vickery Chief Financial Officer
Darren Shafren Chief Scientific Officer
Sarah Prince Company Secretary

Substantial Shareholders

Holding Name
22,931,933 (12.46%) BVF Partners LP
16,420,361 (8.92%) Cormorant Global Healthcare Master Fund, LP
11,288,998 (6.14%) Abingworth LLP
10,671,786 (5.80%) Sabby Healthcare Volatility Master Fund Limited

Calendar of Events

Date Event
16 February 2016 Report (Interim)
23 October 2015 Report (Annual)
26 August 2015 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.